Phase 2 × Lymphoma, Large-Cell, Anaplastic × Filgrastim × Clear all
NCT04195633 2026-02-27

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Fred Hutchinson Cancer Center

Phase 2 Recruiting
60 enrolled
NCT01028716 2023-01-23

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Fred Hutchinson Cancer Center

Phase 2 Terminated
46 enrolled 18 charts
NCT00238368 2017-11-06

Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
59 enrolled
NCT00238433 2017-09-27

Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma

OHSU Knight Cancer Institute

Phase 2 Completed
37 enrolled 8 charts
NCT01110135 2017-05-24

Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma

University of Washington

Phase 2 Completed
43 enrolled 5 charts
NCT00004132 2013-06-26

Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer

National Cancer Institute (NCI)

Phase 2 Completed